Patient has suspected statin-associated muscle symptoms (SAMS)

**CK ≤ 5 x ULN**
- Cease statin for 2-4 weeks

**CK > 5 x ULN OR CK elevation with muscle weakness**
- Cease statin for at least 6-8 weeks until CK within normal range

**Symptoms continue**
- Investigate other causes of muscle symptoms and manage appropriately

**Symptoms improve**
- Resume original statin at reduced dose OR switch to different statin

**Symptoms recur and/or CK > 5 x ULN**
- Cease statin until symptoms resolve and/or CK within normal range

**Symptoms do not recur**
- Switch to low-dose potent statin eg, rosuvastatin 5 mg OR Trial intermittent dosing (eg, once or twice weekly, alternate day)
- Symptoms recur
- Switch to non-statin lipid-modifying medicine, eg, ezetimibe

**Resumes statin**
- Continue statin regimen

**Aim for target LDL-C using the maximum tolerated dose of statin and/or other lipid-modifying medicine**

CK = creatine kinase, LDL-C = low density lipoprotein cholesterol, ULN = upper limit of normal

* CK > ULN and weakness demonstrated upon physical examination.
* Higher potency statins with a long half-life are preferred for intermittent dosing eg, rosuvastatin and atorvastatin

---

**Acknowledgements**

Developed based on the 2012 Therapeutic Guidelines: Cardiovascular and 2016 European Society of Cardiology/European Atherosclerosis Society Guidelines for the management of dyslipidaemias, with input from experts:

Assoc Prof David Colquhoun, Prof Ian Hamilton-Craig, Prof Mark Harris, Assoc Prof Karam Kostner, Prof Leonard Kritharides, Prof Mark Nelson, Dr Daniel Scherer, Assoc Prof David Sullivan, Prof Andrew Tonkin, Mr Garth Birdsey, Dr Chris Helms